Premium
Contributions to the Optimal Use of Human Blood
Author(s) -
Vermeer C.,
Soute B. A. M.,
Ates G.,
Brummelhuis H. G. J.
Publication year - 1976
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1976.tb04830.x
Subject(s) - cryoprecipitate , centrifugation , chemistry , chromatography , blood product , trisodium citrate , fresh frozen plasma , whole blood , medicine , surgery , biochemistry , fibrinogen , platelet
. The influence of different variables on the yield of factor VIII in cryoprecipitate as prepared in the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, was studied. The following conclusions may be drawn:1 In case blood should be stored, the use of the anticoagulant solution acid citrate dextrose (ACD) is preferable to citrate phosphate dextrose (CPD) or trisodium citrate (TSC). 2 The temperature of stored whole blood should not decrease below 8 °C because of a spontaneous precipitation of factor VIII from blood (and plasma) below this temperature. 3 Cryoprecipitate derived from rapidly frozen plasma (1 min) contains a decreased amount of proteins in comparison with cryoprecipitate prepared from slowly frozen plasma (45 min to 4 h). On the other hand, equal amounts of factor VIII activity were obtained in the precipitate after freezing of plasma at varying rates. 4 Rapid thawing of plasma results in both higher yields of factor VIII procoagulant activity and a higher specific activity of this factor in the resulting cryoprecipitate. 5 The sedimentation of cryoprecipitate is completed after 5 min centrifugation at 1,500 g. 6 At temperatures higher than 8 °C, cryoprecipitated factor VIII starts dissolving into the supernatant plasma or in buffer. 7 Factor VIII in lyophilized cryoprecipitate is stable at room temperature. At devated temperatures it rapidly looses its activity. 8 Evidence was obtained that the improvements which are introduced in the preparation of factor VIII do not lead to a product which is less stable in vitro as well as in vivo .